Physician profile

Daniel C Lucio

Internal Medicine · Gretna, LA

NPI 1598751919

$6,210.88

in general payments reported to CMS, 2019-2025

35 companies · $756 in 2025

The $756 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,277.34

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $806.51 2019-2025 Trelegy Ellipta, Shingrix, Arexvy
Abbvie INC. $742.49 2019-2025
Lilly USA, LLC $736.94 2019-2025 Mounjaro, Zepbound, Trulicity
Astrazeneca Pharmaceuticals LP $624.96 2019-2025 Farxiga, Breztri, Airsupra
Amgen INC. $414.38 2019-2023 Evenity, Prolia
Novo Nordisk INC $310.98 2019-2025 Rybelsus, Ozempic, Wegovy
Dexcom, INC. $297.97 2022-2025 Dexcom G6 Transmitter
Boehringer Ingelheim Pharmaceuticals, INC. $285.35 2019-2023 Jardiance
Merck Sharp & Dohme LLC $218.41 2019-2023 Gardasil 9, Vaxneuvance
Sanofi-Aventis U.S. LLC $188.19 2019-2023
Novartis Pharmaceuticals Corporation $186.32 2019-2023
Pfizer INC. $165.15 2019-2025
Abbott Laboratories $163.16 2023-2025 Freestyle Libre 3, Freestyle Libre 2
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $142.04 2019-2024 Xifaxan, Trulance
Janssen Pharmaceuticals, INC $127.06 2019
Show all 35 companies
CompanyGeneral paymentsYearsTop products
Kowa Pharmaceuticals America, INC. $110.77 2019-2023 Livalo
Shield Therapeutics INC $91.73 2023-2024 Accrufer
Ironwood Pharmaceuticals, INC $75.52 2023-2024 Linzess
Takeda Pharmaceuticals U.S.A., INC. $72.46 2019
Amarin Pharma, INC. $60.02 2019
Bayer Healthcare Pharmaceuticals INC. $59.72 2023-2024
E.R. Squibb & Sons, L.L.C. $40.10 2019
Allergan, INC. $37.33 2019
Nevro Corp. $32.55 2019
Teva Pharmaceuticals USA, INC. $29.09 2019
Vanda Pharmaceuticals INC. $27.99 2025 Fanapt
Phadia US INC. $24.61 2019
Astellas Pharma US INC $23.95 2019
Ardelyx, INC. $21.97 2024 Ibsrela
Aytu Biopharma, INC. $19.77 2019
Impel Pharmaceuticals INC. $18.85 2022
Inspire Medical Systems, INC. $14.77 2023 Inspire
Sanofi Pasteur INC. $14.25 2019
Arbor Pharmaceuticals, INC. $13.86 2019
Medtronic USA, INC. $11.66 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel C Lucio

$6,210.88

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $756 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/299663/daniel-c-lucio

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.